(lp0
S"Peregrine Pharmaceuticals : What's Next? Insider Financial - Mar 14, 2017 Our regular readers will be more than aware by now that Peregrine Pharmaceuticals  is a company we keep on coming back to.Company Update : Peregrine Pharmaceuticals Announces Financial ... - Smarter AnalystPeregrine Pharmaceuticals'  CEO Steve King on Q3 2017 Results - Earnings ... - Seeking Alpha"
p1
aS"PEREGRINE PHARMACEUTICALS, INC.  Files An 8-K Other Events Market Exclusive - Mar 9, 2017 Peregrine Pharmaceuticals, Inc.  is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which&nbsp;...Analyst's Predictions on Tidewater Inc. , Peregrine Pharmaceuticals, Inc ... - StockNewsJournal"
p2
aS"Today's Research Reports on Trending Biotech Tickers: Peregrine ... Yahoo Finance - Mar 9, 2017 Peregrine Pharmaceuticals' shares declined 1.86 percent to close at $0.68 a share on Wednesday. The stock traded between $0.65 and $0.69 on volume of 3.18 million shares traded."
p3
aS"Peregrine Pharmaceuticals 's Run Validates Our Thesis Insider Financial - Feb 21, 2017 Our regular readers will know that Peregrine Pharmaceuticals  is one of the companies we have long highlighted as one that we see as being undervalued, and by proxy, due a revaluation.What Next For Peregrine Pharmaceuticals  After Proof of Concept? - StockNewsUnionRevenue Estimates Analysis: Peregrine Pharmaceuticals, Inc.  - News Oracle"
p4
aS'Peregrine Pharmaceuticals  Is One To Watch Ahead Of Earnings Insider Financial - Mar 6, 2017 Our more regular readers will know that Peregrine Pharmaceuticals  is one of the stocks we visit regularly. The company - as we have stated in the past, and an opinion that still stands - is one of the most mis-valued/misunderstood ...Peregrine Pharmaceuticals Inc.: Peregrine to Report Financial Results for ... - The Wall Street TranscriptStock under Consideration: Peregrine Pharmaceuticals, Inc.  - TopChronicle'
p5
aS"BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04 Reuters - Mar 13, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news&nbsp;..."
p6
aS"Ronin Capital Shows New 6.8% Stake in Peregrine Pharmaceuticals  - 13D StreetInsider.com - Mar 2, 2017 Stephen White is the indirect beneficial owner of all of the securities of Peregrine Pharmaceuticals, Inc. held of record or beneficially owned by SW Investment Management LLC by virtue of his having sole voting and dispositive power over such shares.Investor's Alert: Peregrine Pharmaceuticals, Inc.  - TopChroniclePrice Target Overview of Peregrine Pharmaceuticals, Inc.  - FactsReporter"
p7
aS'Watching the ATR on Shares of Peregrine Pharmaceuticals Inc  Rives Journal - 16 hours ago When focusing on technical stock analysis, traders and investors may choose to study the ATR or Average True Range. The present 14-day ATR for Peregrine Pharmaceuticals Inc  is currently standing at 0.93. The ATR basically measures the&nbsp;...'
p8
aS'Average Brokerage Rating Of Peregrine Pharmaceuticals, Inc. , W&amp;T ... The USA Commerce - Mar 17, 2017 Peregrine Pharmaceuticals, Inc.  share price decreased in the last trading session with a previous 52-week high of $0.77.Peregrine Pharmaceuticals  Short Interest Update - Chaffey BreezePeregrine Pharmaceuticals Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p9
aS'PT in Focus For Peregrine Pharmaceuticals, Inc.  Hallador Energy ... Davidson Register - 19 hours ago Equity Research firms currently have a positive stance on shares of Peregrine Pharmaceuticals, Inc. . The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of&nbsp;...'
p10
a.